ARDS On The Move, GLPG Reports Positive Data, PRTO Plunges On PATENCY-2 Results

Today's Daily Dose brings you news about Aridis Pharma's anticipated milestones; Blueprint Medicines' stock offering; Cardax's financial results; ESSA Pharma's progress in prostate cancer program; Gilead Sciences and Galapagos' Filgotinib trial results; Proteon's disappointing PATENCY-2 study data and Supernus Pharma's ADHD trial results.

from RTT - Biotech https://ift.tt/2FL8HKH
via IFTTT